Learning Objectives Year in Review CME Evening (Pre-Conference Evening Event)

The Year in Review will focus on ILD and Lung Transplant

• After the session on ILD, participants will be able to list the most important clinical research in ILD over the past twelve months. Participants will be to apply new therapies for the treatment of ILD. Participants will be able to integrate this new information into their management approach of ILD patients
• After the session on Lung Transplantation, participants will be able to: Demonstrate a practical evidence-informed approach to diagnosing and treating patients with complications post lung transplantation.

Learning Objectives: Annual Day in Respirology

A. Overall Event:

• The UofT Annual Day in Respirology is a one-day conference offering an interactive program focusing on the assessment and treatment of airways diseases in adults. After attending the Annual Day in Respirology, participants will be able to apply evidence-based, updated information in the assessment, testing and treatment of patients with airways diseases.

B. Specific Sessions:

• After the session on chronic cough participants will be able to:
  • Take a relevant history of patients presenting with chronic cough.
  • Incorporate guideline-based diagnostic strategies when working up patients with chronic cough.
  • Incorporate guideline based treatment strategies for patients with chronic cough.
  Reference:
  • ERS guidelines on the diagnosis and treatment of chronic cough in adults and children. Eur Respir J 2020; 55
  • British Thoracic Society Clinical Statement on chronic cough in adults. Parker SM, et al. Thorax 2023;6(suppl 6):3–19.
  • After the session on contemporary management of nasal polyps, participants will be able to:
    • Summarize the surgical and nonsurgical treatments available for nasal polyp management.
    Reference:
    • - The Joint Task Force on Practice Parameters GRADE guidelines for the medical management of chronic rhinosinusitis with nasal polyposis. (J Allergy Clin Immunol 2023;151:386-98.)
  • After the session on non-CF bronchiectasis, participants will be able to:
    • Incorporate guideline-based diagnostic strategies when working up patients with non-CF bronchiectasis.
    • Incorporate guideline based treatment strategies for patients presenting with non-CF bronchiectasis.
    Reference:
    • Bronchiectasis management in adults: state of the art and future directions. Eur Respir J 2024; 63:
  • After the session on diagnostic labeling of airways diseases, participants will be able to:
    • Summarize the various airways phenotypes using the latest diagnostic strategies.
    • Appreciate that accurate phenotyping of airways diseases has an impact on outcomes and management.
    Reference:
    • Bhatt SP, et al. A multidimensional diagnostic approach for chronic obstructive pulmonary disease. JAMA. 2025 May 18.
  • After the session on medical imaging and airways diseases, participants will be able to:
    • Summarize the latest developments in airways imaging and how they may impact future diagnosis and management of airways diseases.
    Reference:
    • New frontiers in asthma chest imaging . (J Allergy Clin Immunol 2025;155:241-54.)
  • After the session on artificial intelligence (AI) in the care of airways diseases, participants will be able to:
    • Summarize the current role of AI in patient management and how AI may impact future patient care.
    Reference:
    • Artificial Intelligence and Machine Learning in Chronic Airway Diseases: Focus on Asthma and Chronic Obstructive Pulmonary Disease. Int. J. Med. Sci. 2021, Vol. 18
    After the session on the Future of COPD, participants will be able to:
    • Summarize the latest developments in the pathobiology of COPD and how this may impact future management of COPD.
    Reference:
    • Bhatt SP, et al. A multidimensional diagnostic approach for chronic obstructive pulmonary disease. JAMA. 2025 May 18.
  • After the session on Biologics in COPD, participants will be able to:
    • Summarize the recent literature supporting biologic therapy and COPD.
    • Understand the role of biologic therapy in patients with severe COPD.
    Reference:
    • Polverino F, Sin DD. Type 2 airway inflammation in COPD. European Respiratory Journal. 2024 May 28;63(5)
  • After the session on inhaler devices, participants will be able to:
    • Understand the impact of inhaler selection on outcomes in patients with airways diseases.
    • Understand the impact of inhaler devices on the environment.
    Reference:
    • Gupta, S., Couillard, S., Digby, G., Tse, S. M., Green, S., Aceron, R., … Penz, E. (2023). Canadian Thoracic Society Position Statement on Climate Change and Choice of Inhalers for Patients with Respiratory Disease. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 7(5), 232–239. https://doi.org/10.1080/24745332.2023.2254283
  • After the session on Th2-guided management of severe asthma and related diseases, participants will be able to:
    • Summarize the diagnostic criteria for severe asthma.
    • Use a guideline based approach to monitor patients with severe asthma.
    • Use a guideline based approach to treat patients with severe asthma.
    Reference:
    • Biologics in severe asthma: a state-of-the-art review. European Respiratory Review 2025 34(175): 240088
  • After the session on Let’s Stick to the FAQs: A Case-Based Panel Discussion, participants will be able to:
    • Discuss controversial topics in the diagnosis and treatment of airways diseases.
    • Optimize the timing of initiation of biologic therapy in patients with complex airways diseases.